Impact of a policy allowing for over-the-counter statins

Quality in Primary Care

Volumn 18, Issue 5, 2010, Pages 301-306

  Mainous III, Arch G ^a,b   Baker, Richard ^c   Everett, Charles J ^a   King, Dana E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Hyperlipidaemia; Self medication; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NON PRESCRIPTION DRUG; SIMVASTATIN;

AGED; ARTICLE; CHI SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; MALE; MIDDLE AGED; UNITED KINGDOM;

AGED; CHI-SQUARE DISTRIBUTION; CORONARY DISEASE; FEMALE; GREAT BRITAIN; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; SIMVASTATIN;

EID: 78650359092     PISSN: 14791072     EISSN: 14791064     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-e171.
2. Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet 2005;366:1267-78.
3. Nag SS, Pearson TA, Ma L et al. Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart disease rates. American Journal of Cardiology 2005;95:862-4.
4. Royal Pharmaceutical Society of Great Britain. Practice Guidance: OTC simvastatin. 2004. www.rpsgb.org.uk/ pdfs/otcsimvastatincardguid.pdf (accessed December 2008).
5. Editorial. OTC statins: a bad decision for public health. The Lancet 2004;363:1659.
6. Tinetti ME. Over-the-counter sales of statins and other drugs for asymptomatic conditions. New England Journal of Medicine 2008;358:2728-32.
7. Rashid S. Should cholesterol-lowering medications be available in Canada without a prescription? Canadian Journal of Cardiology 2007;23:189-93. (Pubitemid 46744758)
8. Brass EP, Vassil T, Replogle A et al. Can consumers selfselect for appropriate use of an over-the-counter statin? The Self Evaluation of Lovastatin to Enhance Cholesterol Treatment Study. American Journal of Cardiology 2008;101:1448-55.
9. Fuster V. A new perspective on nonprescription statins: an opportunity for patient education and involvement. American Journal of Cardiology 2007;100:907-10. (Pubitemid 47268288)
10. Hanford D, Cunningham S, John D, McCaig D and Stewart D. Community pharmacists' views, attitudes and early experiences of over-the-counter simvastatin. Pharmacy World and Science 2007;29:380-5. (Pubitemid 47201831)
11. Filion KB, Delaney JAC, Brophy JM, Ernst P and Suissa S. The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. Pharmacoepidemiology and Drug Safety 2007;16:1-4. (Pubitemid 46164969)
12. Practice Division of the Royal Pharmaceutical Society of Great Britain. Practice Guidance: OTC simvastatin. London: Royal Pharmaceutical Society of Great Britain, 2004.
13. Craig R and Mindell J (eds). Health Survey for England 2006. Volume 3: Methodology and documentation. Leeds: The Information Centre, 2007.
14. National Institute for Health and Clinical Excellence (NICE). Lipid Modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. NICE Clinical Guideline 67. London: NICE, 2008.
15. Anonymous. User Guide, Health Survey for England 2006, Cardiovascular Disease and Risk Factors. London: Joint Health Surveys Unit, National Centre for Social Research, Department of Epidemiology and Public Health, University College London, 2006.
16. Kizer JR, Madias C, Wilner B et al. Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. American Journal of Cardiology 2010;105:1289-96.